Literature DB >> 23185645

Impact of Broadened Coverage of Smoking Cessation Treatments on Cardiovascular Disease.

Paul A Fishman1.   

Abstract

One third of all premature tobacco-attributable deaths are due to CVD and tobacco is the cause of approximately 15% of all CVD attributable. Primary and secondary prevention strategies that combine evidenced based tobacco dependence treatment programs along with cigarette taxes and media campaigns can result in hundreds of thousand of fewer excess deaths from smoking attributable CVD. Expanded insurance from both commercial and public insurers will be greatly expanded by the recently enacted federal health care reform but barriers to reducing the avoidable morbidity and mortality that is due to tobacco use is impacted by the potential for remaining financial barriers to full insurance coverage from Americans in regions of the country with the highest smoking prevalence rates.

Entities:  

Year:  2012        PMID: 23185645      PMCID: PMC3505092          DOI: 10.1007/s12170-012-0275-8

Source DB:  PubMed          Journal:  Curr Cardiovasc Risk Rep        ISSN: 1932-9520


  63 in total

1.  Does insurance coverage for drug therapy affect smoking cessation?

Authors:  Raymond G Boyle; Leif I Solberg; Sanne Magnan; Gestur Davidson; Nina L Alesci
Journal:  Health Aff (Millwood)       Date:  2002 Nov-Dec       Impact factor: 6.301

2.  Tobacco control success versus demographic destiny: examining the causes of the low smoking prevalence in California.

Authors:  Kenneth E Warner; David Mendez; Omar Alshanqeety
Journal:  Am J Public Health       Date:  2008-01-02       Impact factor: 9.308

Review 3.  Prioritizing clinical preventive services: a review and framework with implications for community preventive services.

Authors:  Michael V Maciosek; Ashley B Coffield; Nichol M Edwards; Thomas J Flottemesch; Leif I Solberg
Journal:  Annu Rev Public Health       Date:  2009       Impact factor: 21.981

4.  State estimates of Medicaid expenditures attributable to cigarette smoking, fiscal year 1993.

Authors:  L S Miller; X Zhang; T Novotny; D P Rice; W Max
Journal:  Public Health Rep       Date:  1998 Mar-Apr       Impact factor: 2.792

5.  Short term effects of cigarette smoking on hospitalisation and associated lost workdays in a young healthy population.

Authors:  A S Robbins; V P Fonseca; S Y Chao; G A Coil; N S Bell; P J Amoroso
Journal:  Tob Control       Date:  2000-12       Impact factor: 7.552

6.  Cigarette tax increase and media campaign cost of reducing smoking-related deaths.

Authors:  Paul A Fishman; Beth E Ebel; Michelle M Garrison; Dimitri A Christakis; Sarah E Wiehe; Frederick P Rivara
Journal:  Am J Prev Med       Date:  2005-07       Impact factor: 5.043

7.  Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes.

Authors:  Clara K Chow; Sanjit Jolly; Purnima Rao-Melacini; Keith A A Fox; Sonia S Anand; Salim Yusuf
Journal:  Circulation       Date:  2010-02-01       Impact factor: 29.690

8.  Evaluation of the economic impact of California's Tobacco Control Program: a dynamic model approach.

Authors:  Leonard S Miller; Wendy Max; Hai-Yen Sung; Dorothy Rice; Malcolm Zaretsky
Journal:  Tob Control       Date:  2010-04       Impact factor: 7.552

9.  A longitudinal study of medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in hospitalizations for cardiovascular disease.

Authors:  Thomas Land; Nancy A Rigotti; Douglas E Levy; Mark Paskowsky; Donna Warner; Jo-Ann Kwass; Leann Wetherell; Lois Keithly
Journal:  PLoS Med       Date:  2010-12-07       Impact factor: 11.069

Review 10.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.

Authors:  Judith J Prochaska; Joan F Hilton
Journal:  BMJ       Date:  2012-05-04
View more
  1 in total

Review 1.  Cardiometabolic risk in polycystic ovary syndrome.

Authors:  Katica Bajuk Studen; Marija Pfeifer
Journal:  Endocr Connect       Date:  2018-05-29       Impact factor: 3.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.